Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncology Research and Treatment

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000484206PMID 29485411
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

  2017cited by this paper
• Mechanisms of retinoic acid signalling and its roles in organ and limb development

  2015cited by this paper
• Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution

  2015cited by this paper
• Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

  2015cited by this paper
• Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.

  2014cited by this paper
• Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib

  2014cited by this paper
• Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

  2013cited by this paper
• Aumento della captazione del radioiodio indotto da selumetinib in pazienti con cancro della tiroide

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment

  2013cited by this paper
• Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

  2012cited by this paper
• New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review

  2012cited by this paper
• Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma.

  2011cited by this paper
• Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience

  2011cited by this paper
• Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

  2011cited by this paper
• Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

  2011cited by this paper
• Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.

  2009cited by this paper
• Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer

  2009cited by this paper
• 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

  2009cited by this paper
• Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer.

  2009cited by this paper
• Dedifferentiated thyroid cancer: a therapeutic challenge.

  2008cited by this paper
• BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

  2008cited by this paper
• Rosiglitazone Effect on Radioiodine Uptake in Thyroid Carcinoma Patients with High Thyroglobulin but Negative Total Body Scan: A Correlation with the Expression of Peroxisome Proliferator–Activated Receptor-Gamma

  2008cited by this paper
• Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

  2006cited by this paper
• Defective Efficacy of Retinoic Acid Treatment in Patients with Metastatic Thyroid Carcinoma

  2006cited by this paper
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005cited by this paper
• Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors.

  2005cited by this paper
• Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.

  2005cited by this paper
• Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma

  2004cited by this paper
• Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.

  2004cited by this paper
• A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer.

  2004cited by this paper
• Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

  2003cited by this paper
• Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study

  2002cited by this paper
• Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET

  2002cited by this paper
• Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.

  1998cited by this paper
• Redifferentiation Therapy with Retinoids: Therapeutic Option for Advanced Follicular and Papillary Thyroid Carcinoma

  1998cited by this paper
• Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.

  1997cited by this paper
• All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study

  1994cited by this paper
• Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines.

  1994cited by this paper
• Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro.

  1990cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• [Carcinoma].

  1955cited by this paper
• Transformations Related to the Angular and the Square Root

  1950cited by this paper
• Cáncer

  1939cited by this paper
• American

  1898cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary

  year unknowncited by this paper

• In-vitro Assessment of the Proliferation and Apoptosis of Thyroid Cancer Cells Using Valproic Acid and Retinoic Acid Alone and in Combination with Etoposide and Epirubicin

  2025cites this paper
• Modulation of Intestinal Flora: a Novel Immunotherapeutic Approach for Enhancing Thyroid Cancer Treatment

  2025cites this paper
• Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

  2024cites this paper
• Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.

  2023cites this paper
• Downregulation of cellular retinoic acid binding protein 1 fosters epithelial–mesenchymal transition in thyroid cancer

  2023cites this paper
• Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers.

  2022cites this paper
• Personalized Diagnosis in Differentiated Thyroid Cancers by Molecular and Functional Imaging Biomarkers: Present and Future

  2022cites this paper
• The relationship between thyroid disorders and vitamin A.: A narrative minireview

  2022cites this paper
• Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer

  2021cites this paper
• Therapiekonzepte beim Schilddrüsenkarzinom

  2021cites this paper
• Therapiekonzepte beim Schilddrüsenkarzinom

  2021cites this paper
• Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS

  2021cites this paper
• Disruption by stealth - Interference of endocrine disrupting chemicals on hormonal crosstalk with thyroid axis function in humans and other animals.

  2021cites this paper
• Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis

  2020cites this paper
• Redifferentiation of radioiodine-refractory thyroid cancers.

  2020cites this paper
• Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines

  2019cites this paper